While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

Aubagio, a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS), has been approved by the US Food and Drug Administration (FDA). Aubagio (teriflunomide ...